BookYasuhiko Tomino., editor
Contents:
Part I. Pathogenesis
Chapter 1. Is IgA nephropathy the same disease/a homogenous disease?
Chapter 2. Genetic variations of IgA nephropathy
Chapter 3. Is IgA nephropathy a familial or sporadic disease?
Chapter 4. Heterogeneity of GdIgA1
Chapter 5. Differences of histological classification between the Japanese guideline and the Oxford classification
Chapter 6. Podocyte injury and the role of megalin
Chapter 7. Complement activation
Part II. Treatment
Chapter 8. How different are the current understandings of treatments for IgA nephropathy?
Chapter 9. Differences in etiology and treatment in China
Chapter 10. Differences in etiology and treatment in Korea
Chapter 11. Differences in etiology and treatment in Japan
Chapter 12. The VALIGA study: Differences in treatment approaches within the EU
Chapter 13. Differences in etiology and treatment in Scandinavian countries
Chapter14 The Implication of the KDIGO Clinical Practice Guidelines on management of IgA Nephropathy
Chapter15 Japanese Clinical Practice Guidelines for IgA Nephropathy: Difference from KDIGO Guidelines
Chapter16 Limitations of RAS blockade in IgA nephropathy
Chapter17 What is the goal for proteinuria in IgA nephropathy?
Chapter 18. Rationale of tonsillectomy and steroid pulse therapy (TSP): Is it race dependent?
Chapter 19. Is tonsillectomy a possible treatment for IgA nephropathy from RCT?
Chapter 20. Is tonsillectomy a possible treatment for IgA nephrology from a retrospective analysis?.